The purpose of this resource is to provide tissue, cells and pathology services to all 5 research projects andcareer or research development awardees covered by this application. The plan for this Lymphoma SPOREis to combine pathology resources of the Dan L Duncan Cancer Center at Baylor College of Medicine (BCM)and its affiliated institutions with those of The Methodist Hospital to ensure adequate numbers and timelydelivery of tissue/cell samples for the projected needs of project investigators. It will therefore co-ordinateacquisition of tissue for banking from lymphoma and CLL patients at 5 affiliated hospitals in the TexasMedical Center, by relying on tissue collection and distribution systems already in place. The capacity toobtain samples from 5 affiliated hospitals will greatly increase the number of specimens we are able toanalyze, store and distribute. The core will also provide pathology services including routine tissuepreparation, immunohistochemical staining, laser capture microdissection, preparation of tissue microarrays,flow cytometry, detection of minimal residual disease and in situ hybridization for viral RNAs. These tasksare essential to the successful completion of planned experiments in each project and will be performed byexpert pathologists and histotechnologists with substantial experience in providing core services to SPOREinvestigators. We believe the resultant Tissue Core will have the necessary laboratory space, equipment andhuman resources to handle the workload outlined for the Lymphoma SPORE. This core also containsbioinformatics support to support tissue-banking software needs for the lymphoma core and includesinvestigators with expertise in developing CDEs and experience working with the BCM Prostate SPOREs todevelop a caBIG compliant system linking biospecimen data.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA126752-01
Application #
7253736
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (J1))
Project Start
2007-04-01
Project End
2012-03-31
Budget Start
2007-09-11
Budget End
2008-08-31
Support Year
1
Fiscal Year
2007
Total Cost
$313,763
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Brunetti, Lorenzo; Gundry, Michael C; Kitano, Ayumi et al. (2018) Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9. J Vis Exp :
Xiong, Wei; Chen, Yuhui; Kang, Xi et al. (2018) Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells. Mol Ther 26:963-975
Heslop, Helen E; Brenner, Malcolm K (2018) Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy. Mol Ther 26:1-2
Hogstad, Brandon; Berres, Marie-Luise; Chakraborty, Rikhia et al. (2018) RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med 215:319-336
Mamonkin, Maksim; Mukherjee, Malini; Srinivasan, Madhuwanti et al. (2018) Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res 6:47-58
Velasquez, Mireya Paulina; Bonifant, Challice L; Gottschalk, Stephen (2018) Redirecting T cells to hematological malignancies with bispecific antibodies. Blood 131:30-38
Kalra, Mamta; Gerdemann, Ulrike; Luu, Jessica D et al. (2018) Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy. Cytotherapy :
Ngai, Ho; Tian, Gengwen; Courtney, Amy N et al. (2018) IL-21 Selectively Protects CD62L+ NKT Cells and Enhances Their Effector Functions for Adoptive Immunotherapy. J Immunol 201:2141-2153
Morita, Daisuke; Nishio, Nobuhiro; Saito, Shoji et al. (2018) Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells. Mol Ther Methods Clin Dev 8:131-140
Bollard, Catherine M; Tripic, Tamara; Cruz, Conrad Russell et al. (2018) Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol 36:1128-1139

Showing the most recent 10 out of 270 publications